EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Study sponsor: NovoCure GmbH
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-10Actual
Enrollment · participants15Actual
Source updated2025-04-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.